Combination treatment for myocardial infarction shows no added benefit compared to ASA monotherapy - Hallo friendsLET'S HEALTHY LIFE, In the article you read this time with the title Combination treatment for myocardial infarction shows no added benefit compared to ASA monotherapy, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cough, Article diabetes, Article diseases, Article in general, Article Phytotherapy, Article skin diseases, We write this you can understand. Alright, good read.

Title : Combination treatment for myocardial infarction shows no added benefit compared to ASA monotherapy
link : Combination treatment for myocardial infarction shows no added benefit compared to ASA monotherapy

Combination treatment for myocardial infarction shows no added benefit compared to ASA monotherapy

The drug ticagrelor has been approved since February 2016 for adults who had a myocardial infarction a year or more ago and are at a high risk of a new myocardial infarction or stroke. Ticagrelor is used together with low-dose acetylsalicylic acid (ASA). In its dossier assessment published in early July 2016, the German Institute for Quality and Efficiency in Health Care (IQWiG) determined an indication of a minor added benefit of ticagrelor in comparison with the administration of ASA alone.

 acetylsalicylic acid(ASA)   Ticagrelor

On the inclusion of additional analyses that the drug manufacturer provided in the commenting procedure conducted by the Federal Joint Committee (G-BA), the Institute now came to a different conclusion, however: An added benefit is not proven because positive effects are called into question by negative effects.

Non-severe bleeding notably more common

The dossier had only contained data on severe bleeding. There were no data on non-severe bleeding that are clinically relevant. The results of the analyses subsequently submitted by the manufacturer were to the disadvantage of ticagrelor: Since these bleeding events were notably more common than under ASA monotherapy, IQWiG determined proof of greater harm with the extent "considerable".

No data on quality of life

In addition, there were no data on quality of life. Particularly in coronary heart disease (CHD), this is a very important outcome criterion however, which is even more important in view of side effects such as dyspnoea. "Disease-related quality of life" is the first treatment goal listed in the recently published revised version of the National Care Guideline for Coronary Heart Disease.

Since, on the one hand, greater harm was proven for an additional outcome, and, on the other, no data on quality of life were available, the positive effects, including the ones regarding mortality and late complications, were called into question by the negative effects. In the overall consideration, no added benefit of ticagrelor plus ASA in comparison with ASA monotherapy could be derived from the data.

Combination treatment for myocardial infarction shows no added benefit compared to ASA monotherapy: The drug ticagrelor has been approved since February 2016 for adults who had a myocardial infarction a year or more ago and are at a high risk of a new myocardial infarction or stroke.

Medicinal Chemistry

Thus Article Combination treatment for myocardial infarction shows no added benefit compared to ASA monotherapy

That's an article Combination treatment for myocardial infarction shows no added benefit compared to ASA monotherapy This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Combination treatment for myocardial infarction shows no added benefit compared to ASA monotherapy with the link address https://letslifes.blogspot.com/2017/07/combination-treatment-for-myocardial.html

Tweet

Subscribe to receive free email updates: